The World Health Organization recommends swapping non-nucleoside reverse transcriptase inhibitors (NNRTI) regimens for a dolutegravir-based combination because of widening resistance to NNRTIs.1 To help guide this transition, this comparison of switch strategies in people with a viral load below or above 1000 copies was conducted in the VISEND study. Dr Nyuma Mbewe (University of Zambia, Lusaka, Zambia) joins touchINFECTIOUSDISEASES to discuss this study.
The presentation entitled ‘Incident tuberculosis as a risk factor for viral non-suppression 48 weeks among patients switched to dolutegravir based therapy with recycled nucleoside reverse transcriptase inhibitors in Lusaka, Zambia’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
Questions:
- Â What did the VISEND study teach us about the use of dolutegravir and recycled tenofovir and lamivudine in people with HIV?
- What were the aims, design, and findings of the current sub-analysis of the VISEND data?
- Based on this analysis, what are your recommendations for clinical practice and for further study?
Disclosures: Nyuma Mbewe has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
- Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO.
